Microbiome, Dietary and Quality of Life Analysis of People Living With CVID Treated With or Without Immunoglobulins.

September 21, 2026 updated by: Universitair Ziekenhuis Brussel

Our research group focusses on finding evidence-based diet strategies to overcome immune dysregulation either due to immune checkpoint inhibitors (ICI) or common variable immunodeficiency (CVID) (Figure 1). CVID is an inborn error of immunity, which is defined, among other factors, by a low level of immunoglobulins, resulting in an increased risk of infections, auto-immune/inflammatory diseases, and cancer.

The gut microbiome (GM) plays a crucial role in maintaining immune homeostasis and modulating the host's innate and adaptive immune responses. Modulation of the GM can be achieved by dietary interventions that have been demonstrated to change the composition of the GM within 2 weeks (Oliver et al., 2021). The intake of more than 30 different plant products (vegetables, fruits, seeds and grains) on a weekly basis is associated with a more diverse microbiome in healthy adults (McDonald et al., 2018). Although direct proof of a link between diet and functioning of the immune system is lacking, it is striking that in a retrospective study, melanoma patients treated with immune checkpoint inhibitors (ICI) had a better overall survival when they consumed enough fibers without taking probiotics (Spencer et al., 2021). Currently, we have included 54 of 60 foreseen patients receiving ICI in an interventional study (FORX-01 (NCT05832606)) at our centre, providing them weekly with 30 different plants to be integrated in their diet (funded by Delhaize and FWO). The aim is to measure if the interventional group develops less immune-related adverse events (= side effects of ICI) by changing their GM.

Similarly, we hypothesize that introducing a fiber-rich diet in patients with CVID will result in a more diverse GM leading to a decrease in autoimmune disorders and infections and as such lead to an improvement of quality of life. To challenge this hypothesis, we plan to organize a similar diet trial, called KNIVES. To prepare this study, we will first perform an observational study to describe the microbiome of people with CVID (DELICIOUS) followed at UZ Brussel.

Study Overview

Status

Enrolling by invitation

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

70

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Belgie
      • Ninove, Belgie, Belgium, 9400
        • Universitair Ziekenhuis Brussel
    • Brussels Capital
      • Brussels, Brussels Capital, Belgium, 1090
        • Universitair ziekenhuis Brussel

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • CVID diagnosis according to ESID criteria
  • 18y or older

Exclusion Criteria:

  • start of therapeutic doses of antibiotics < 30 days prior to inclusion
  • start of an immunomodulator < 30 days prior to inclusion Patient excluded for the above reasons will be able to step in the study at a later timepoint (30 days after start of antibiotics of immunomodulators)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: CVID participants of Observational cohort

Participants assigned to this arm will follow a high-fiber dietary intervention according to the study protocol. Clinical outcomes, gastrointestinal symptoms, dietary intake, and biological samples will be collected throughout the study to assess the effects of the intervention.

Participants receive individualized dietary counseling to increase their dietary fiber intake and follow a high-fiber diet according to the study protocol throughout the intervention period.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Primary outcomes
Time Frame: 1 year

To describe the gut microbiome of people living with CVID followed at UZ Brussel.

To perform microbiome analysis through metagenomics (depending on availability, pricing, and emerging literature).

To analyze one faecal sample of each participant at inclusion and additionally during infectious or autoinflammatory events.

To assess microbiome diversity and composition, including:

Alpha-diversity. Beta-diversity. Firmicutes/Bacteroidetes ratio (as a proximal marker for dysbiosis).

Abundance of specific short-chain fatty acid-producing genera, including:

Prevotella. Lactobacillaceae. Bifidobacteriaceae. Lachnospiraceae.

1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Secondary outcome
Time Frame: 1 year
  1. Dietary pattern assessment: Collection and analysis of 3-day food diaries at baseline according to Nubel, with focus on fiber intake.
  2. CVID characteristics assessment: Classification of patients based on infectious complications, dysimmune complications, and IgA deficiency status.
  3. Fatigue Severity Scale (Krupp et al., 1989).
  4. CVID_QoL questionnaire (Quinti et al., 2016).
  5. EQ-5D questionnaire.
  6. IBS Symptom Severity Scale.
  7. Rome PI-IBS Questionnaire.
  8. Rome IV Diagnostic Questionnaire for Adult Functional Gastrointestinal Disorders (R4DQ).
  9. Gastrointestinal Symptom Rating Scale (GSRS).
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 15, 2026

Primary Completion (Estimated)

August 1, 2028

Study Completion (Estimated)

September 1, 2028

Study Registration Dates

First Submitted

September 21, 2026

First Submitted That Met QC Criteria

September 21, 2026

First Posted (Actual)

September 28, 2026

Study Record Updates

Last Update Posted (Actual)

September 28, 2026

Last Update Submitted That Met QC Criteria

September 21, 2026

Last Verified

July 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • DELICIOUS

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe